Dinaciclib
- Generic Name
- Dinaciclib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H28N6O2
- CAS Number
- 779353-01-4
- Unique Ingredient Identifier
- 4V8ECV0NBQ
- Background
Dinaciclib has been used in trials studying the treatment of rrMM, rrCLL, rrDLBCL, Solid Tumors, and Solid Neoplasm, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-03-30
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT03484520
- Locations
- 🇺🇸
David Geffen School of Medicin /ID# 200015, Los Angeles, California, United States
🇺🇸The Ohio State University /ID# 200668, Columbus, Ohio, United States
🇦🇺Gold coast University Hospital /ID# 202759, SouthPort, Queensland, Australia
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 75
- Registration Number
- NCT02684617
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT01783171
- Locations
- 🇺🇸
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸University of Colorado, Denver, Colorado, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT01711528
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-31
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Jo Chien
- Target Recruit Count
- 32
- Registration Number
- NCT01676753
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
- Conditions
- Interventions
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5
- Registration Number
- NCT01650727
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-06-20
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT01624441
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)
- Conditions
- Interventions
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 44
- Registration Number
- NCT01580228
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT01515176
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 121
- Registration Number
- NCT01434316
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.